



Announcement Summary

Entity name

CLINUVEL PHARMACEUTICALS LIMITED

Announcement Type

New announcement

Date of this announcement

Friday October 03, 2025

Details of +securities that have ceased

| ASX +security code | Security description | Number of +securities that have ceased | The +securities have ceased due to | Date of cessation |
|--------------------|----------------------|--|---|-------------------|
| CUVAK | PERFORMANCE RIGHTS | 36,323 | Expiry of option or other convertible security without exercise or conversion | 01/10/2025 |

Refer to next page for full details of the announcement



Part 1 - Announcement Details

1.1 Name of +Entity

CLINUVEL PHARMACEUTICALS LIMITED

We (the entity named above) provide the following information about our issued capital.

1.2 Registered Number Type

ABN

Registration Number

88089644119

1.3 ASX issuer code

CUV

1.4 The announcement is

New announcement

1.5 Date of this announcement

3/10/2025

Part 2 - Details of +equity securities or +debt securities that have ceased

ASX +Security Code and Description

CUVAK : PERFORMANCE RIGHTS

Unquoted +equity securities that have ceased**Number of securities that have ceased**

22,123

Reason for cessation

Expiry of option or other convertible security without exercise or conversion

Date of cessation

1/10/2025

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?

ASX +Security Code and Description

CUVAK : PERFORMANCE RIGHTS

Unquoted +equity securities that have ceased**Number of securities that have ceased**

14,200

Reason for cessation

Lapse of conditional right to securities because the conditions have not been, or have become incapable of being, satisfied

Date of cessation

1/10/2025

Is the entity paying any consideration for the cessation?

No

Any other information the entity wishes to notify to ASX about the cessation?

Shares on issue: 50,123,630 + 58,627 (per App 2A lodged 3 Oct 2025) + 18,483 (per App 2A lodged 3 Oct 2025) = 50,200,740

Performance Rights on issue: 499,825 - 58,627 (per App 2A lodged 3 Oct 2025) - 22,123 (per this App 3H) - 14,200 (per this App 3H) = 404,875

Part 3 - Issued capital following changes

Following the cessation of the +securities the subject of this notification, the issued capital of the entity will comprise:

The figures in parts 3.1 and 3.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

3.1 Quoted +equity securities and +debt securities (total number of each +class of +securities quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| CUV : ORDINARY FULLY PAID | 50,123,630 |

3.2 Unquoted +equity securities (total number of each +class of +equity securities issued but not quoted on ASX)

| ASX +security code and description | Total number of +securities on issue |
|---|---|
| CUVAK : PERFORMANCE RIGHTS | 463,502 |

Note: the figures stated in the tables above are used to calculate the total market capitalisation of the entity published by ASX from time to time. The table will not include those classes of +securities that have ceased or lapsed in their entirety in ASX records before the announcement date described in Q1.5, even if the entity has advised ASX of a change to that class of +security in Part 2 of this form.